{"id":"W2898353693","doi":"10.1093/annonc/mdy287.074","title":"IMvoke010: Randomized phase III study of atezolizumab (atezo) as adjuvant monotherapy after definitive therapy of squamous cell carcinoma of the head and neck (SCCHN)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Atezolizumab; Oncology; Head and neck; Adjuvant; Internal medicine; Basal cell; Head and neck cancer; Adjuvant therapy; Cancer; Immunotherapy; Surgery; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001308439,0.001366325,0.002883053,0.0003088629,0.0003576559,0.001252052,0.001118844,0.00142251,0.005153884],"category_scores_gemma":[0.001034468,0.0007381366,0.001595323,0.0003275578,0.001069902,0.001073855,0.0004297688,0.004014552,0.001249545],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008839213,"about_ca_system_score_gemma":0.001449068,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001575067,"about_ca_topic_score_gemma":0.005154447,"domain_scores_codex":[0.9996735,0.0001300119,0.0000175623,0.00006852391,0.00002584826,0.00008461428],"domain_scores_gemma":[0.9994659,0.000120403,0.00008766725,0.00005520384,0.00003156289,0.0002392842],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9552949,0.007873005,0.001399148,0.0005581913,0.0008078954,0.0000394895,0.00005545963,0.0006272194,0.004725953,0.0001682737,0.001651531,0.02679896],"study_design_scores_gemma":[0.9095913,0.08451786,0.003027219,0.00003047059,0.0004821856,0.00005176381,0.00003345267,0.0004817198,0.0005920575,0.0001416095,0.001031692,0.00001871792],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9882655,0.003666534,0.0006182914,0.0005658488,0.0007233804,0.001949138,0.001354718,0.0001383694,0.002718193],"genre_scores_gemma":[0.9816841,0.003039337,0.001388063,0.001414095,0.0004477157,0.002463885,0.002910164,0.00006020197,0.00659229],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005153884,"threshold_uncertainty_score":0.01724148,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04919813182413135,"score_gpt":0.3708233703394067,"score_spread":0.3216252385152753,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}